1,027 material Form 8-K filings that 835 companies we cover made with the SEC in February 2025, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). All of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
MasTec reported fourth quarter and full-year 2024 results on February 27, 2025, with revenue and GAAP net income both higher than in 2023. The company also issued initial 2025 guidance, including $13.45 billion in revenue and GAAP net income of $327 million to $366 million, and expects a GAAP net loss of $1 million in the first quarter of 2025.
Q4 2024 revenue was $3.4 billion, up from $3.3 billion; GAAP net income was $84.7 million, versus $1.2 million in Q4 2023.
Full-year 2024 GAAP net income was $199.4 million, or $2.06 per diluted share, compared with a net loss of $47.3 million in 2023.
2025 guidance: revenue of $13.45 billion, GAAP diluted EPS of $3.75 to $4.24, and adjusted EBITDA of $1.10 billion to $1.15 billion.
Estimated 18-month backlog reached a record $14.3 billion at December 31, 2024; net debt leverage ratio was 1.8x.
Tidewater reported fourth-quarter 2024 revenue of $345.1 million, up from $302.7 million a year earlier, while quarterly net income of $36.9 million ($0.70 per diluted share) was roughly flat against $37.7 million ($0.70) in the prior-year quarter. The company also initiated 2025 revenue guidance of $1.32 billion to $1.38 billion and approved a new share repurchase program of up to $90.3 million, which management said is the maximum permitted under its existing debt agreements.
Q4 2024 revenue of $345.1 million, compared with $302.7 million for Q4 2023
Q4 2024 net income of $36.9 million ($0.70 per diluted share), compared with $37.7 million ($0.70) for Q4 2023
Full-year 2024 net income of $180.7 million ($3.40 per diluted share), up 85.9% from 2023
2025 guidance: revenue of $1.32 billion to $1.38 billion and gross margin of 48% to 50%; new buyback authorization of $90.3 million
Targa Resources Corp. completed a $2.0 billion underwritten offering of senior notes due 2035 and 2055, each $1.0 billion. The company expects to use part of the proceeds to repurchase the outstanding preferred equity in Targa Badlands LLC, which holds its North Dakota assets, for about $1.8 billion in cash. For shareholders, this is a large debt-funded transaction that adds long-term borrowing while buying out a joint venture partner's stake.
$1.0 billion of 5.550% Senior Notes due 2035 and $1.0 billion of 6.125% Senior Notes due 2055 were issued on February 27, 2025.
Proceeds are expected to fund a roughly $1.8 billion cash repurchase of joint venture partner's preferred equity in Targa Badlands LLC, expected to close in the first quarter of 2025.
If the Badlands transaction does not close, proceeds will go to general corporate purposes, including repaying commercial paper borrowings.
Arcosa reported fourth quarter 2024 revenue up 14% to $666.2 million, helped by the $1.2 billion Stavola acquisition completed October 1, 2024, but posted a net loss of $7.7 million versus net income of $27.1 million a year earlier. Acquisition-related expenses of $15.6 million and higher interest expense weighed on results, while Adjusted EBITDA rose 52% to $128.3 million. The company guided to 2025 revenues of $2.8 billion to $3.0 billion and Adjusted EBITDA of $545 million to $595 million, with GAAP profit trends and guidance pointing in different directions for shareholders.
Q4 2024 revenue was $666.2 million, up 14% from $582.2 million; net loss was $7.7 million, or $0.16 per diluted share, versus net income of $27.1 million, or $0.56 per share, in Q4 2023.
Q4 Adjusted EBITDA rose 52% to $128.3 million; Adjusted Diluted EPS fell 32% to $0.46 from $0.68.
Full year 2025 guidance: consolidated revenues of $2.8 billion to $3.0 billion and Adjusted EBITDA of $545 million to $595 million.
Q4 free cash flow was $199.2 million; year-end net debt to Adjusted EBITDA was 2.9x, down from 3.4x at the end of the third quarter.
Assured Guaranty reported fourth quarter 2024 net income attributable to the company of $18 million, or $0.35 per diluted share, down from $376 million, or $6.40 per share, a year earlier. The prior-year quarter included a $208 million benefit from tax law changes, and full-year 2024 net income fell to $376 million, or $6.87 per share, from $739 million, or $12.30 per share. For shareholders, the decline in reported earnings is large, though the company also repurchased $502 million of shares in 2024.
Q4 2024 adjusted operating income was $66 million, or $1.27 per share, versus $338 million, or $5.75 per share, in Q4 2023.
Full-year 2024 adjusted operating income was $389 million, or $7.10 per share, versus $648 million, or $10.78 per share, in 2023.
Q4 2024 total revenues were $156 million, versus $327 million in Q4 2023; full-year revenues were $872 million, versus $1,373 million.
As of February 27, 2025, the company was authorized to buy back about $276 million of its common shares, and it expects a gain of about $103 million in Q1 2025 from the LBIE litigation.
HP reported fiscal first-quarter revenue of $13.5 billion, up 2.4% from a year earlier, while GAAP diluted EPS fell to $0.59 from $0.62. HP also approved an expansion of its restructuring plan, adding about $0.3 billion in annualized savings and about $150 million in charges, with 1,000 to 2,000 additional gross workforce reductions, and it held its fiscal 2025 outlook.
Q1 fiscal 2025 net revenue $13.5 billion, up 2.4%; GAAP diluted EPS $0.59 versus $0.62, within the $0.57 to $0.63 outlook
Non-GAAP diluted EPS $0.74 versus $0.81 a year earlier, within the $0.70 to $0.76 outlook
Restructuring amendment adds about $0.3 billion in fiscal 2025 savings, bringing the total to about $1.9 billion, with about $150 million in additional charges
Incremental gross workforce reductions of about 1,000 to 2,000 employees, varying by country; fiscal 2025 non-GAAP EPS outlook of $3.45 to $3.75 held
Solventum agreed on February 25, 2025 to sell its purification and filtration business to Thermo Fisher Scientific for approximately $4.10 billion in cash, plus assumption of certain liabilities, subject to customary closing adjustments. The deal is subject to closing conditions, including antitrust clearance, and Solventum expects to close by the end of 2025, so shareholders face a pending divestiture rather than a completed sale.
Cash consideration of approximately $4.10 billion payable at closing, subject to adjustments for cash, debt, transaction expenses and working capital
Agreement dated February 25, 2025; Solventum expects to close by the end of the 2025 calendar year
Either party may terminate if the deal is not completed by November 25, 2025, with two three-month extensions available if only regulatory conditions remain unmet
Solventum agreed to a three-year non-compete for the business and a two-year non-solicit and no-hire for certain employees after closing
American Healthcare REIT reported fourth-quarter and full-year 2024 results on February 27, 2025, and issued full-year 2025 guidance. The fourth-quarter GAAP net loss per diluted share narrowed to $(0.21) from $(0.42) a year earlier, and normalized FFO per diluted share rose to $0.40 from $0.38, while full-year normalized FFO was $1.41 versus $1.40 in 2023. For 2025, the company expects normalized FFO of $1.56 to $1.60 per diluted share and total portfolio same-store NOI growth of 7.0% to 10.0%.
Q4 2024 GAAP net loss attributable to controlling interest was $(31.8) million, or $(0.21) per diluted share, versus $(27.4) million, or $(0.42), in Q4 2023.
Full-year 2024 normalized FFO was $1.41 per diluted share; total portfolio same-store NOI grew 17.7%.
2025 guidance: normalized FFO of $1.56 to $1.60 per diluted share and net income of $0.26 to $0.30 per diluted share, versus a 2024 net loss of $(0.29).
Company raised about $1.36 billion of gross equity in 2024, including $120.2 million through its at-the-market program in Q4.
Masco Corporation's board elected Heath M. Eisman, 50, as Vice President, Controller and Chief Accounting Officer, effective February 27, 2025. He previously served as the company's Director, Financial Reporting since 2014 and will receive a $310,000 annual base salary with incentive programs targeting 40% of salary. The change is a senior finance leadership appointment that shareholders may want to note, though the filing describes no change in company results or strategy.
Heath M. Eisman, 50, elected by the board on February 26, 2025, effective February 27, 2025
Annual base salary of $310,000, with target incentive opportunity of 40% of base salary under annual and long-term programs
Payouts capped at 200% of target; annual restricted stock unit award equal in value to 40% of base salary
Prior role: Director, Financial Reporting at Masco since 2014; earlier at Caterpillar Inc. and PricewaterhouseCoopers
Solventum reported fourth-quarter 2024 sales up 1.9% to $2.074 billion, but GAAP diluted EPS fell to $0.17 from $1.57 a year earlier, and adjusted EPS fell to $1.41 from $2.17. The company also introduced 2025 guidance for organic sales growth, adjusted EPS and free cash flow, but said the guidance still includes the Purification and Filtration segment it agreed to sell and will be updated after that deal closes.
Q4 2024 sales were $2.074 billion, up 1.9%; organic sales rose 2.3%
GAAP operating income was $136 million versus $406 million a year earlier; adjusted operating margin was 20.4% versus 25.9%
2025 guidance: organic sales growth of 1.0% to 2.0%, adjusted EPS of $5.45 to $5.65, free cash flow of $450 million to $550 million
Guidance includes Purification and Filtration, which Solventum announced it would sell on February 25, 2025
DoubleVerify reported fourth-quarter 2024 revenue of $190.6 million, up 11% from a year earlier, but net income fell to $23.4 million from $33.1 million. The company also agreed to acquire Rockerbox for $85 million in cash and guided first-quarter 2025 revenue to $151 million to $155 million, with full-year 2025 revenue growth of about 10%. Shareholders see revenue growth alongside lower profit, plus a new acquisition that adds to the company's spending.
Q4 2024 revenue of $190.6 million, up 11%; Q4 net income of $23.4 million versus $33.1 million in Q4 2023
Full-year 2024 revenue of $656.8 million, up 15%; full-year net income of $56.2 million versus $71.5 million in 2023
Q1 2025 revenue guidance of $151 million to $155 million; full-year 2025 revenue growth of approximately 10%
Agreed to acquire Rockerbox, Inc. for $85 million in cash, subject to customary adjustments, announced February 26, 2025
Acadia Healthcare reported fourth-quarter 2024 revenue of $774.2 million, up 4.2% from a year earlier, but net income attributable to Acadia fell to $32.6 million, or $0.35 per diluted share, from $57.7 million, or $0.63, in the prior-year quarter. The company also issued 2025 guidance, including revenue of $3.3 to $3.4 billion and adjusted EPS of $2.50 to $2.80, and authorized a $300 million share repurchase program.
Q4 2024 revenue $774.2 million, up 4.2%; adjusted EBITDA $153.1 million versus $171.6 million a year earlier
Full-year 2024 revenue $3.15 billion, up 7.7%; net income attributable to Acadia $255.6 million versus a loss of $21.7 million in 2023
2025 guidance: revenue $3.3 to $3.4 billion, adjusted EBITDA $675 to $725 million, adjusted EPS $2.50 to $2.80
Board authorized share repurchases of up to $300 million with no expiration date; conference call scheduled February 28, 2025
Sunrun reported fourth-quarter and full-year 2024 results. Revenue was flat in Q4 and down 10% for the year, and a $3.1 billion non-cash goodwill impairment drove a large GAAP net loss. The company reported Cash Generation of $34.2 million in Q4 and gave 2025 Cash Generation guidance of $200 million to $500 million.
Q4 2024 total revenue was $518.5 million, up $1.9 million, or 0%, from Q4 2023; full-year 2024 revenue was $2.0 billion, down 10%.
Q4 2024 net loss attributable to common stockholders was $2.8 billion, or $12.51 per share, including the $3.1 billion goodwill impairment; non-GAAP net income was $360.9 million, or $1.41 per diluted share.
2025 Cash Generation guidance is $200 million to $500 million for the full year and $40 million to $50 million for Q1 2025.
Astrana Health entered an amended and restated credit agreement on February 26, 2025, with Truist Bank as agent and a group of lenders. The facilities total $1.295 billion, including a $745 million delayed draw term loan to finance an acquisition under a November 8, 2024 purchase agreement with Prospect Medical Holdings. The new debt terms replace the company's 2021 credit agreement and carry leverage and interest coverage covenants, plus a security interest in the company's assets.
Revolving credit facility of $300 million, term loan A of $250 million and delayed draw term loan of $745 million, all five-year facilities
Delayed draw term loan funds an asset and equity acquisition from Prospect Medical Holdings, Inc. under an agreement dated November 8, 2024
Interest rate spreads of 1.25% to 2.50% over term SOFR, set quarterly by leverage ratio; covenants require maximum net leverage of 5.00 to 1.00, stepping down to 4.50 to 1.00 after March 31, 2027, and minimum interest coverage of 2.50 to 1.
Separate 2025 Annual Meeting of Stockholders set for June 11, 2025, held virtually, with a record date of April 22, 2025
Edison International reported fourth-quarter 2024 net income of $340 million, or $0.88 per share, down from $378 million, or $0.99 per share, a year earlier. Full-year 2024 GAAP EPS rose to $3.33 from $3.12, and core EPS rose to $4.93 from $4.76. The company revised its 2025 core EPS guidance to $5.94-$6.34, which includes the impact of the TKM settlement, and the filing does not state the prior range.
Q4 2024 core EPS was $1.05, compared with $1.28 a year earlier; core earnings were $405 million versus $490 million.
Full-year 2024 operating revenue was $17.6 billion, up from $16.3 billion in 2023.
TKM settlement approved, authorizing $1.6 billion of cost recovery for pre-AB 1054 wildfire costs.
Quarterly dividend of $0.8275 per share declared, payable April 30, 2025, to holders of record on April 7, 2025.
Central Pacific Financial Corp. said its Boards approved, effective March 1, 2025, the promotion of David Morimoto, the current Chief Financial Officer, to Vice Chairman and Chief Operating Officer, and of Dayna Matsumoto, Director of Finance and Accounting, to Executive Vice President and Chief Financial Officer. The change moves the company's top finance role to a new executive and sets new pay terms for both, which shareholders may want to track in future filings.
David Morimoto, age 57, becomes Vice Chairman and COO effective March 1, 2025; he has been CFO since July 2015 and joined the company in 1991. His base salary will be $525,000, with a target incentive of 75% of salary and a maximum of 150%.
Dayna Matsumoto, age 43, becomes EVP and CFO effective March 1, 2025; she has been Director of Finance and Accounting since 2023 and joined the company in 2006. Her base salary will be $362,000, with a target incentive of 50% of salary and
The filing discloses that Matsumoto's husband, Patrick Matsumoto, is a Vice President and Commercial Real Estate Manager at the Bank, with total 2024 compensation of approximately $177,000.
Mosaic reported fourth quarter and full year 2024 results. Full-year net sales fell 19% to $11.1 billion and net income fell 85% to $175 million, with a $642 million foreign exchange loss weighing on results. Management expects phosphate and potash volumes to recover in 2025 and gave production, sales volume, price and capital expenditure assumptions for the year.
Q4 2024 net income was $169 million, down from $365 million in Q4 2023; Q4 adjusted EBITDA was $594 million versus $646 million
Full-year 2024 adjusted EBITDA was $2.2 billion, down 20% from 2023; full-year diluted EPS was $0.55
Notable items reduced 2024 EPS by $1.43, mainly a $642 million foreign currency transaction loss, partly offset by a $522 million Ma'aden gain
2025 guidance includes potash production of 8.7-9.1 million tonnes and phosphate production of 7.2-7.6 million tonnes, with capital expenditures of $1.2-1.3 billion
Medical Properties Trust reported a fourth-quarter 2024 net loss of $413 million ($0.69 per share) and a full-year net loss of $2.4 billion ($4.02 per share), including about $415 million of impairments and fair market value adjustments tied to Prospect Medical Group and PHP Holdings. Normalized FFO fell to $0.18 per share for the quarter from $0.36 a year earlier and to $0.80 for the year from $1.59. The company said a $2.5 billion senior secured notes offering addresses all debt maturities through 2026.
Q4 2024 net loss of $413 million ($0.69 per share) versus $664 million ($1.11 per share) in Q4 2023
Q4 2024 normalized FFO of $0.18 per share versus $0.36; full-year 2024 normalized FFO of $0.80 versus $1.59
Full-year 2024 net loss of $2.4 billion ($4.02 per share) versus $556 million ($0.93 per share) in 2023
Private offering of more than $2.5 billion of senior secured notes due 2032 at a blended coupon of 7.885%
Moelis & Company said Christopher Callesano, its Managing Director and Principal Accounting Officer, will become Chief Financial Officer effective March 31, 2025. He succeeds Joseph Simon, who resigned on February 25, 2025 after a 15-year tenure and will leave at the end of May. The change gives shareholders a known internal successor and a transition period, with no financial results reported in the filing.
Christopher Callesano appointed CFO effective March 31, 2025; has been with Moelis since 2010
Joseph Simon resigned February 25, 2025 and will leave the company at the end of May 2025
Nick Riehl appointed Principal Accounting Officer effective March 31, 2025, succeeding Callesano in that role
On February 27, 2025, Viatris reported fourth quarter and full-year 2024 results and issued 2025 guidance. Full-year 2024 total revenues were $14.7 billion, down 5% as reported, and the U.S. GAAP net loss was $634.2 million, compared with net earnings of $54.7 million in 2023. The company guided 2025 total revenues to $13.5 billion to $14.0 billion and adjusted EPS to $2.12 to $2.26, and said an FDA import alert at its Indore facility is expected to reduce 2025 total revenues by about $500 million and adjusted EBITDA by about $385 million.
Full-year 2024 total revenues were $14.7 billion, down 5% as reported; adjusted EPS was $2.65, versus $2.93 in 2023.
U.S. GAAP net loss was $(634.2) million for 2024, compared with net earnings of $54.7 million in 2023.
2025 guidance: total revenues of $13.5 billion to $14.0 billion and adjusted EPS of $2.12 to $2.26.
Indore facility impact is estimated at about $500 million to 2025 total revenues and about $385 million to adjusted EBITDA; the company plans $500 million to $650 million in 2025 share repurchases.
Frontdoor reported full-year 2024 revenue up 4% to $1.84 billion, net income up 37% to $235 million, and diluted earnings per share up 42% to $3.01. For 2025, it projects revenue of $2.0 billion to $2.04 billion and Adjusted EBITDA of $450 million to $475 million, including the 2-10 Home Buyers Warranty acquisition.
Full-year 2024 Adjusted EBITDA rose 28% to $443 million, and gross profit margin expanded 410 basis points to 54%.
Fourth-quarter 2024 revenue rose 5% to $383 million, while net income was flat at $9 million.
The 2025 outlook includes a gross profit margin of 51.5% to 53% and Adjusted EBITDA of $450 million to $475 million.
The company repurchased $160 million of shares in 2024 and will hold a 2025 Investor Day on February 27, 2025.
Installed Building Products reported fourth-quarter 2024 net revenue up 4.1% to a record $750.2 million, with net income up 3.1% to $66.9 million, or $2.39 per diluted share. For the full year, net revenue rose 5.9% to a record $2.9 billion and diluted EPS rose to $9.10 from $8.61, and the Board approved a 6% higher quarterly dividend and a $1.70 annual variable dividend payable March 31, 2025.
Q4 2024 net income $66.9 million, or $2.39 per diluted share, versus $64.9 million, or $2.29, a year earlier
Full-year 2024 net income $256.6 million, or $9.10 per diluted share, versus $8.61 in 2023
Quarterly cash dividend of $0.37 per share and annual variable dividend of $1.70 per share, payable March 31, 2025 to holders of record March 14, 2025
New stock repurchase program of up to $500 million, expiring March 1, 2026
J.M. Smucker reported fiscal third-quarter results for the period ended January 31, 2025, with net sales down 2% to $2.2 billion and a GAAP net loss of $6.22 per diluted share, driven by $794.3 million and $208.2 million noncash impairment charges tied to Sweet Baked Snacks. Adjusted EPS rose 5% to $2.61, and the company raised the low and high ends of its fiscal 2025 adjusted EPS guidance while lowering its net sales growth outlook.
Net sales were $2,186.0 million, down $43.2 million or 2% from the prior-year quarter.
Net loss per diluted share was $6.22, including a $794.3 million goodwill impairment and a $208.2 million trademark impairment.
Adjusted EPS was $2.61, up 5%; free cash flow was $151.3 million versus $249.6 million a year earlier.
Fiscal 2025 adjusted EPS guidance was updated to $9.85 to $10.15 from $9.70 to $10.10; net sales growth guidance is 7.25% versus 7.50% to 8.50% previously.
AAON reported fourth-quarter 2024 net sales down 2.9% to $297.7 million and diluted EPS down 46.4% to $0.30 from $0.56, with AAON Oklahoma sales down 16.1%. Full-year 2024 net sales rose 2.7% to $1.2 billion, backlog ended the year at $867.1 million, up 70.0%, and management expects margins to stay under pressure early in 2025. The Board also authorized up to $100.0 million in open-market share repurchases.
Q4 gross profit fell 30.5% to $77.6 million and operating income fell 53.9% to $29.4 million.
Full-year 2024 net sales rose 2.7% to $1.2 billion, while diluted EPS fell 5.2% to $2.02.
Backlog was $867.1 million at December 31, 2024, up 70.0% from a year earlier.
The Board authorized up to $100.0 million in share repurchases, to be executed based on market conditions.
Macerich reported fourth-quarter 2024 results on February 27, 2025, showing a net loss attributable to the company of $211.2 million, or $0.89 per diluted share, compared with net income of $62.2 million, or $0.29 per share, a year earlier. Total revenues rose to $273.7 million from $238.7 million, but FFO excluding certain items fell to $116.7 million ($0.47 per share) from $127.7 million ($0.57 per share), so shareholders face a weaker quarter on the company's core measures despite higher revenue.
Total revenues were $273.7 million in Q4 2024, up from $238.7 million in Q4 2023.
Net loss attributable to the company was $211.2 million ($0.89 per diluted share), versus net income of $62.2 million ($0.29 per share) a year earlier.
FFO excluding certain items was $116.7 million ($0.47 per share), down from $127.7 million ($0.57 per share).
Same center NOI, excluding lease termination income, fell 0.4% in Q4 2024; portfolio occupancy was 94.1% at December 31, 2024. The quarterly dividend is $0.17 per share, payable March 18, 2025.
PENN Entertainment reported fourth-quarter 2024 revenue of $1,669.0 million, up from $1,395.4 million a year earlier, and a net loss of $133.8 million, narrowed from $358.8 million. The company also said it intends to repurchase at least $350 million of shares in 2025, which matters to shareholders because it signals a large capital return alongside improved results.
Q4 2024 diluted loss per share was $(0.88), compared with $(2.37) in Q4 2023.
Adjusted EBITDA was $165.2 million, compared with a loss of $(39.6) million in the prior-year quarter.
Interactive segment revenue was $275.0 million, compared with $31.5 million a year earlier, including a tax gross-up of $132.8 million.
Full-year 2024 net loss was $313.3 million, compared with $491.4 million in 2023.
Unum's Unum Life Insurance Company of America subsidiary agreed on February 26, 2025 to cede $3.4 billion of long-term care statutory reserves and a 100% quota share of certain Provident Life and Accident individual disability business to Fortitude Reinsurance Company Ltd. The company expects an overall capital benefit, offset in part by a pre-tax ceding commission of approximately $430 million, and closing is expected during 2025. The filing also cites a revised 2025 EPS growth outlook of 6-10%, while the company's presentation says it expects a capital benefit of about $100 million from the transaction.
Reinsures $3.4 billion of long-term care statutory reserves, 19% of total LTC statutory reserves
Pre-tax ceding commission of approximately $430 million paid as consideration for the reinsurance
Estimated capital benefit of about $100 million per the news release
Closing expected during 2025, subject to regulatory approvals; agreement may be terminated if not closed within six months
TechnipFMC reported fourth-quarter 2024 revenue of $2,367.3 million, up 13.9% from a year earlier, and net income of $224.7 million, or $0.52 per diluted share, up from $0.12 a year earlier but down 18.2% from the prior quarter. The company raised its 2025 subsea revenue guidance to $8.4-8.8 billion and said 2025 shareholder distributions would grow at least 30%, which matters to shareholders because it signals higher expected revenue and cash returns. Net income included a discrete non-cash tax benefit of $54 million.
Q4 2024 revenue was $2,367.3 million, up 13.9% year over year, and adjusted diluted EPS was $0.54, versus $0.14 a year earlier.
Subsea 2025 revenue guidance was raised to $8.4-8.8 billion from $8.3-8.7 billion; subsea adjusted EBITDA margin guidance is 19-20%, up from 18.5-20%.
Net income included a discrete non-cash tax benefit of $54 million; the company returned $486 million to shareholders in 2024.
Management expects 2025 shareholder distributions to be at least 70% of free cash flow, driving growth of at least 30% year over year.
Life Time Group Holdings reported fourth-quarter 2024 revenue of $663.3 million, up 18.7%, and net income of $37.2 million, up 57.0%. For the full year, revenue rose 18.2% to $2,621.0 million and net income more than doubled to $156.2 million, and the company raised its 2025 outlook based on early 2025 results.
Net debt leverage ratio improved to 2.28x at December 31, 2024, from 3.61x a year earlier
2025 guidance: revenue $2,925 million to $2,975 million, net income $277 million to $284 million, adjusted EBITDA $780 million to $800 million, all raised from January 16, 2025 guidance
Full-year free cash flow of $273.6 million, including $207.4 million of sale-leaseback proceeds
First Advantage reported fourth quarter and full year 2024 results, which include costs from its Sterling acquisition, closed October 31, 2024. Full year revenue rose to $860.2 million from $763.8 million, but the company posted a net loss of $110.3 million versus net income of $37.3 million a year earlier, and adjusted diluted EPS fell to $0.82 from $1.00. The company also introduced 2025 guidance of $1.5 billion to $1.6 billion in revenue and $410 million to $450 million in adjusted EBITDA.
Full year 2024 revenue was $860.2 million, compared with $763.8 million in 2023
Full year 2024 GAAP net loss was $110.3 million, including $130.5 million of expenses tied to the Sterling acquisition
Full year 2024 adjusted diluted EPS was $0.82, compared with $1.00 in 2023
2025 guidance: revenue $1.5 billion to $1.6 billion; adjusted EBITDA $410 million to $450 million; adjusted diluted EPS $0.86 to $1.03
LifeStance's board promoted David Bourdon, the company's CFO since 2022, to Chief Executive Officer effective March 3, 2025, succeeding Kenneth Burdick, who is retiring as CEO and will serve as Executive Chairman. Ryan McGroarty was named Chief Financial Officer and Treasurer effective March 17, 2025, to succeed Bourdon in that role. The filing does not include financial results.
Bourdon becomes CEO effective March 3, 2025, with a $700,000 annual base salary and a target bonus of 100% of base salary.
Burdick, CEO since 2022, retires as CEO and becomes Executive Chairman with a $200,000 annual base salary.
McGroarty becomes CFO effective March 17, 2025, with a $550,000 base salary, a target bonus of 85% of base salary, and a $570,000 one-time signing bonus.
McGroarty's one-time equity award has an aggregate target grant date value of approximately $5,000,000.
Acushnet reported full-year 2024 net sales of $2.46 billion, up 3.2%, and net income attributable to the company of $214.3 million, up $15.9 million, with fourth-quarter net loss narrowing to $1.1 million from $26.8 million a year earlier. The company also gave a 2025 outlook of $2.49 billion to $2.54 billion in net sales and $405 million to $420 million in Adjusted EBITDA, and raised its quarterly dividend 9.3% and added a $250.0 million share repurchase authorization.
Full-year 2024 Adjusted EBITDA was $404.4 million, up 7.5%, and fourth-quarter Adjusted EBITDA was $12.4 million versus a $1.5 million loss a year earlier
2025 outlook calls for net sales of $2,485 million to $2,535 million and Adjusted EBITDA of $405 million to $420 million, including an estimated negative currency impact of about $35 million
Quarterly cash dividend increased 9.3% to $0.235 per share, payable March 21, 2025 to holders of record as of March 7, 2025
On February 13, 2025, the board authorized an additional $250.0 million in share repurchases, bringing the total authorization to $1.25 billion
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.